ArticleBMC infectious diseases2026
Multidrug-resistant Acinetobacter spp. bloodstream infections in hematologic patients: clinical characteristics, genomic features, and eravacycline-based combination therapy.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundMultidrug-resistant (MDR) Acinetobacter spp. bloodstream infection (BSI) is concerning in hematologic patients, but integrated clinical and genomic analyses are scarce.
methodsWe retrospectively analyzed 62 hematologic patients with Acinetobacter spp. BSI over 13 years, including 30 MDR and 32 non-MDR cases. Whole-genome sequence (WGS) was conducted on 23 MDR isolates. Checkerboard assays evaluated the in vitro activity of eravacycline combined with sulbactam, meropenem, cefoperazone-sulbactam, polymyxin B, and levofloxacin.
resultsFemale (66.67% vs. 34.38%, P = 0.022) and adult (≥ 14 years; 80.00% vs. 53.12%, P = 0.049) patients were more common in the MDR group. Prior carbapenem exposure, prolonged neutropenia, and respiratory tract colonization were associated with MDR-BSI. The majority of MDR cases did not receive appropriate empirical therapy within 24 h (40.00% vs. 90.62%, P < 0.001). The overall 30-day mortality was 38.71%, significantly higher in MDR than non-MDR patients (53.33% vs. 25.00%, P = 0.043). Among MDR subgroup, 30-day non-survivors had more profound cytopenias and higher inflammatory markers at BSI onset (P < 0.05). WGS revealed diverse sequence types and capsular loci across the isolates, including 14 non-A.baumannii and 9 A.baumannii strains. Among 20 carbapenemase-positive isolates, bla
conclusionsEravacycline exhibited strong in vitro activity and favorable synergy with sulbactam, supporting its potential role in treating MDR Acinetobacter spp. infections in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.